OverviewChartNewsTraderScreen

Cogstate Ltd./  AU000000CGS8  /

Nasdaq Other OTC
2024-05-07  3:30:02 PM Chg. -0.0212 Volume Bid- Ask- High Low
0.8788USD -2.36% 1,000
Turnover: 878.8000		 -Bid Size: - -Ask Size: - 0.8788 0.8788
GlobeNewswire 2023-10-17 Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders
GlobeNewswire 2022-01-13 EISAI TO LAUNCH DIGITAL TOOL "CogMate™ IN TAIWAN AND HONG KONG
GlobeNewswire 2022-01-10 Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patien...
GlobeNewswire 2021-12-01 Clinical Trial in Dementia with Lewy Bodies Used Cogstate Digital Assessments and Data Quality Servi...
GlobeNewswire 2020-11-16 Leaders from Cogstate Join the Davos Alzheimer’s Collaborative to Accelerate Innovation and Prepared...
GlobeNewswire 2020-10-01 Cogstate Expands Executive Team with Key Scientific Appointments
GlobeNewswire 2020-04-29 Cogstate Receives Digital Biomarker Award from ADDF to Develop Mobile App for Early Detection of Mem...
GlobeNewswire 2020-01-27 Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) P...
GlobeNewswire 2020-01-27 Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial disea...
GlobeNewswire 2019-11-19 Cogstate Expands Executive Team, Appointing Ken Billard as Chief Commercial Officer
GlobeNewswire 2018-10-16 Probiodrug publishes SAPHIR data in peer reviewed journal
GlobeNewswire 2018-07-13 Global Cognition & Memory Enhancement Drugs Market 2018-2022: Drivers, Trends and Opportunities
GlobeNewswire 2018-05-15 Probiodrug AG reports First Quarter 2018 Business Update
GlobeNewswire 2018-05-10 IntelGenx Reports First Quarter 2018 Financial Results
GlobeNewswire 2018-04-05 Cogstate Establishes Rare Disease and Pediatric Center of Excellence
GlobeNewswire 2018-01-24 IntelGenx Initiates Phase 2A Montelukast Versafilm™ Clinical Trial in Alzheimer’s Patients
GlobeNewswire 2017-12-05 Neuralstem Presents Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive Disorder...
GlobeNewswire 2017-11-04 Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANA...
GlobeNewswire 2017-10-12 Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate A...
GlobeNewswire 2017-05-12 Probiodrug AG reports First Quarter 2017 Business Update
GlobeNewswire 2017-03-30 Probiodrug reports full year 2016 financial results
GlobeNewswire 2017-01-09 Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase I...
GlobeNewswire 2016-12-08 Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate ...
GlobeNewswire 2016-12-08 Probiodrug: Innovative Phase II study design of Glutaminylcyclase Inhibitor PQ912 in early Alzheimer...
GlobeNewswire 2016-11-22 Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimer’...